Workflow
辰欣药业(603367) - 2021 Q3 - 季度财报
CISENCISEN(SH:603367)2021-10-26 16:00

Financial Performance - The company's revenue for Q3 2021 was ¥925,611,868.13, representing a decrease of 6.72% compared to the same period last year[7]. - Net profit attributable to shareholders was ¥102,805,324.26, down 29.59% year-over-year[7]. - The net profit excluding non-recurring gains and losses was ¥95,104,992.10, reflecting a decline of 34.40% compared to the previous year[7]. - Basic earnings per share for the quarter was ¥0.23, a decrease of 28.13% year-over-year[10]. - Total operating revenue for the first three quarters of 2021 reached ¥2,757,165,803.14, an increase from ¥2,650,423,323.06 in the same period of 2020, representing a growth of approximately 4.03%[27]. - Net profit for the first three quarters of 2021 was ¥285,356,646.18, down from ¥324,268,916.56 in 2020, reflecting a decrease of approximately 12.0%[31]. - The company reported a total comprehensive income of ¥282,770,077.00 for the first three quarters of 2021, down from ¥324,268,916.56 in 2020, reflecting a decline of approximately 12.8%[33]. - Basic earnings per share for the first three quarters of 2021 were ¥0.63, compared to ¥0.72 in the same period of 2020, indicating a decrease of about 12.5%[33]. Assets and Liabilities - Total assets at the end of the quarter were ¥5,930,758,153.06, a decrease of 3.81% from the end of the previous year[10]. - The total assets as of September 30, 2021, are ¥5,930,758,153.06, down from ¥6,165,710,473.50, indicating a decrease of approximately 3.8%[25]. - The total current assets decreased to ¥3,678,286,204.04 from ¥3,950,229,934.55, a decline of about 6.9%[21]. - The total current liabilities decreased to ¥882,860,412.46 from ¥1,284,346,085.73, a reduction of about 31.3%[25]. - The company's long-term liabilities total ¥76,996,973.66, slightly down from ¥79,419,298.50, showing a decrease of about 3.0%[25]. - The total liabilities as of the end of the reporting period were ¥959,857,386.12, down from ¥1,363,765,384.23 in the previous year[27]. - The total equity attributable to shareholders reached ¥4,970,050,015.40, an increase from ¥4,800,949,979.60 in the previous year, representing a growth of approximately 3.5%[27]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥34,523,486.64, down 88.94% compared to the same period last year[10]. - Cash inflow from operating activities totaled ¥2,489,959,044.60, an increase from ¥2,448,595,895.13 in the same period last year, representing a growth of approximately 1.9%[36]. - Cash outflow from operating activities amounted to ¥2,455,435,557.96, compared to ¥2,136,406,965.28 in the previous year, indicating a rise of about 14.9%[36]. - Net cash flow from operating activities was ¥34,523,486.64, a significant decrease from ¥312,188,929.85 year-over-year[36]. - Cash inflow from investment activities reached ¥3,287,397,033.53, a substantial increase from ¥230,420,786.38 in the prior year[38]. - Net cash flow from investment activities was ¥96,315,512.66, down from ¥134,834,826.39 in the same period last year[38]. - Cash inflow from financing activities totaled ¥138,000,000.00, a decrease from ¥331,201,507.49 year-over-year[38]. - Net cash flow from financing activities was -¥321,274,279.08, compared to a positive cash flow of ¥13,865,098.48 in the previous year[38]. - The ending cash and cash equivalents balance was ¥468,067,499.93, down from ¥821,034,253.90 at the end of the same period last year[38]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,051[15]. - The largest shareholder, Chenxin Technology Group Co., Ltd., holds 165,673,200 shares, accounting for 36.54% of total shares[15]. Inventory and Receivables - The inventory as of September 30, 2021, is ¥646,847,634.97, an increase from ¥572,118,681.59, reflecting an increase of approximately 13%[21]. - The accounts receivable increased to ¥585,265,758.74 from ¥498,901,812.25, representing an increase of about 17.3%[21]. Research and Development - Research and development expenses for the first three quarters of 2021 amounted to ¥246,409,047.63, compared to ¥224,431,128.43 in 2020, showing an increase of about 9.8%[31]. - The company has no significant new product or technology developments reported in the current quarter[19].